Sandoz, Inc. recalled 1,680 bottles of Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension on August 13, 2025. The recall stems from temperature abuse that may compromise the product's efficacy. Consumers should stop using the product immediately and contact their healthcare provider or Sandoz for guidance.
Temperature Abuse
Consumers and healthcare providers should stop using this product immediately. Contact Sandoz Inc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, Rx only, manufactured by Novartis Manufacturing NV in Belgium. It has the NDC# 0781-6186-67 and was distributed to one consignee in California.
The recall is due to temperature abuse, which can affect the stability and effectiveness of the medication. This presents a high hazard level as improper storage conditions can lead to insufficient treatment.
No specific incidents of injury or adverse effects have been reported related to this recall. However, the potential for compromised treatment is a significant concern.
Stop using the product immediately. Contact Sandoz, Inc. or your healthcare provider for further guidance. Notification will occur via letter.
For more information, contact Sandoz, Inc. at their customer service number or visit their official website.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.